Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Batefenterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 20/20 | 1.00 |
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Batefenterol SCHEMBL384465 | 1.00 | ADRB2 (1.00) | ADRB2CHRM3CHRM2 | |
| Batefenterol SCHEMBL384466 | 1.00 | ADRB2 (1.00) | ADRB2CHRM3CHRM2 | |
| Batefenterol SCHEMBL385358 | 1.00 | ADRB2 (1.00) | ADRB2CHRM3CHRM2 | |
| Batefenterol SCHEMBL29372665 | 1.00 | ADRB2 (1.00) | ADRB2CHRM3CHRM2 | |
| Batefenterol SCHEMBL1999609 | 0.98 | ADRB2 (0.97) | ADRB2CHRM3CHRM2 | |
| Batefenterol SCHEMBL29380164 | 0.98 | ADRB2 (0.97) | ADRB2CHRM3CHRM2 | |
| Batefenterol SCHEMBL380875 | 0.96 | ADRB2 (0.93) | ADRB2CHRM3CHRM2 | |
| SCHEMBL19173093 | 0.94 | ADRB2 (0.90) | ADRB2CHRM3CHRM2 | |
| SCHEMBL741252 | 0.94 | CHRM3 (1.00) | ADRB2CHRM3CHRM2 | |
| SCHEMBL827897 | 0.94 | ADRB2 (0.88) | ADRB2CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12006329-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-11623932-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006329-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | ADRB2 4774/4885CHRM3 4866/4885CHRM2 4861/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | ADRB2 4774/4885CHRM3 4866/4885CHRM2 4861/4885 |
| US-11623932-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | ADRB2 4774/4885CHRM3 4866/4885CHRM2 4861/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | ADRB2 4774/4885CHRM3 4866/4885CHRM2 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.